Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Abbott Laboratories : Third-Quarter Results Beat Views With Revenue Getting COVID-19 Test Boost as Full-Year EPS Outlook Lifted

10/20/2021 | 09:42am EST


ę MT Newswires 2021
All news about ABBOTT LABORATORIES
11/18INSIDER SELL : Abbott Laboratories
MT
11/17Abbott launches similac 360 total care with exclusive blend of five hmo prebiotics and ..
AQ
11/16Abbott Laboratories Launches Similac 360 Total Care Infant Formula
MT
11/16Abbott Launches Similac« 360 Total Care« with Exclusive Blend of Five HMO Prebiotics an..
PR
11/16Abbott Launches Similac? 360 Total Care? with Exclusive Blend of Five Hmo Prebiotics an..
CI
11/16Talis Biomedical Names Brian Blaser Chief Executive
MT
11/15Abbott Achieves Highest Score in Its Industry for the Ninth Consecutive Year on the Dow..
PR
11/15Abbott's new leadless pacemaker system meets primary endpoints in pivotal trial
AQ
11/12Abbott Laboratories Says its New Leadless Pacemaker Meets Safety, Efficacy Endpoints
MT
11/12Abbott Laboratories New Leadless Pacemaker System Meets Primary Endpoints in Pivotal Tr..
CI
More news
Analyst Recommendations on ABBOTT LABORATORIES
More recommendations
Financials (USD)
Sales 2021 42 030 M - -
Net income 2021 6 560 M - -
Net Debt 2021 8 142 M - -
P/E ratio 2021 34,0x
Yield 2021 1,34%
Capitalization 223 B 223 B -
EV / Sales 2021 5,49x
EV / Sales 2022 5,67x
Nbr of Employees 109 000
Free-Float 88,5%
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | MarketScreener
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 125,88 $
Average target price 135,94 $
Spread / Average Target 7,99%
EPS Revisions
Managers and Directors
Robert B. Ford President, CEO, Chief Operating Officer & Director
Robert Emmett Funck Chief Financial Officer & Executive VP-Finance
Miles D. White Executive Chairman
Sabina Ewing Chief Investment Officer, VP-Business & Technology
Roxanne Schuh Austin Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ABBOTT LABORATORIES14.97%222 592
MEDTRONIC PLC-5.20%149 347
BECTON, DICKINSON AND COMPANY-2.05%69 611
HOYA CORPORATION27.96%59 428
DEXCOM, INC.60.11%57 374
SARTORIUS STEDIM BIOTECH76.99%53 762